RCS - N4 Pharma PLC - Investor Presentation via Investor Meet Company

N4 PharmaAnnouncement

09/10/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231009:nRSI0167Pa&default-theme=true

RNS Number : 0167P  N4 Pharma PLC  09 October 2023

Reach Non-regulatory

 

 

9 October 2023

 

N4 Pharma Plc

("N4 Pharma" or the "Company")

Investor Presentation via Investor Meet Company

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for oncology, gene therapy and vaccines, is
pleased to announce that Nigel Theobald (CEO) and Paul Murray (Nanogenics)
will provide an update following the Company's acquisition of Nanogenics via a
live presentation on the Investor Meet Company platform on 16 October 2023 at
2.00pm BST.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9.00am the day before the meeting or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet N4
Pharma Plc via:

 

https://www.investormeetcompany.com/n4-pharma-plc/register-investor
(https://www.investormeetcompany.com/n4-pharma-plc/register-investor)

 

Investors who already follow N4 Pharma Plc on the Investor Meet Company
platform will automatically be invited.

 

Enquiries:

 

 N4 Pharma Plc                                          Via IFC Advisory

 Nigel Theobald, CEO

 Luke Cairns, Executive Director

 SP Angel Corporate Finance LLP                         Tel: +44 (0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre/Rob Rees (Corporate Broking)

 Turner Pope Investments (TPI) Limited                  Tel: +44 (0)20 3657 0050

 Joint Broker

 Andy Thacker

 IFC Advisory Limited                                   Tel: +44 (0)20 3934 6630

 Financial PR

 Graham Herring

 Zach Cohen

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel
antigens in these fields to use Nuvec® as the delivery vehicle for these
antigens. As these products progress through pre-clinical and clinical
programs, N4 Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the market.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAMFBBTMTTMBAJ